Literature DB >> 17889033

Changes in the activation level of NF-kappa B in lymphocytes of MS patients during glucocorticoid pulse therapy.

Martin Eggert1, Robert Goertsches, Ulrike Seeck, Silvia Dilk, Gunther Neeck, Uwe K Zettl.   

Abstract

Nuclear factor-kappaB activity was analyzed in multiple sclerosis (MS) patients during the course of a methylprednisolone pulse therapy. Molecular effects were evaluated using lymphocytes derived from 20 MS patients before and after therapy and 24 healthy individuals. All patients responded to treatment clinically. The mean level of DNA-binding p65 in MS was proportionate to that of healthy controls, but was significantly decreased directly after therapy whereas the level of DNA-binding p50 was significantly elevated prior to therapy and remained unchanged. In summary, pulse therapy resulted in a decreased level of activated p65 NF-kappaB subunits leading to decreased levels of transcriptionally active pro-inflammatory NF-kappaB.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17889033     DOI: 10.1016/j.jns.2007.08.026

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  12 in total

1.  Promoter-specific induction of the phosphatase SHP-1 by viral infection and cytokines in CNS glia.

Authors:  George P Christophi; Chad A Hudson; Ross Gruber; Christoforos P Christophi; Paul T Massa
Journal:  J Neurochem       Date:  2008-06-01       Impact factor: 5.372

2.  Inflammation in the spotlight-clinical relevance of genetic variants affecting nuclear factor κB and tumor necrosis factor receptor 1.

Authors:  Francisco J Ortega; José M Fernández-Real
Journal:  Ann Transl Med       Date:  2017-05

3.  Genetic variants associated with autoimmunity drive NFκB signaling and responses to inflammatory stimuli.

Authors:  William J Housley; Salvador D Fernandez; Kenneth Vera; Sasidhar R Murikinati; Jaime Grutzendler; Nicole Cuerdon; Laura Glick; Phillip L De Jager; Mitja Mitrovic; Chris Cotsapas; David A Hafler
Journal:  Sci Transl Med       Date:  2015-06-10       Impact factor: 17.956

4.  Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients.

Authors:  George P Christophi; Ross C Gruber; Michael Panos; Rebecca L Christophi; Burk Jubelt; Paul T Massa
Journal:  Clin Immunol       Date:  2011-12-02       Impact factor: 3.969

5.  Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-β 1a treated multiple sclerosis patients.

Authors:  George P Christophi; Jennifer A Christophi; Ross C Gruber; Cornelia Mihai; Luis J Mejico; Paul T Massa; Burk Jubelt
Journal:  J Neurol Sci       Date:  2011-06-11       Impact factor: 3.181

6.  Induced liver injury after high-dose methylprednisolone in a patient with multiple sclerosis.

Authors:  Ana Torres Oliveira; Sandra Lopes; Maria Augusta Cipriano; Carlos Sofia
Journal:  BMJ Case Rep       Date:  2015-07-21

7.  Modulation of macrophage infiltration and inflammatory activity by the phosphatase SHP-1 in virus-induced demyelinating disease.

Authors:  George P Christophi; Chad A Hudson; Michael Panos; Ross C Gruber; Paul T Massa
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

8.  Interferon-beta treatment in multiple sclerosis attenuates inflammatory gene expression through inducible activity of the phosphatase SHP-1.

Authors:  George P Christophi; Michael Panos; Chad A Hudson; Chriso Tsikkou; Cornelia Mihai; Luis J Mejico; Burk Jubelt; Paul T Massa
Journal:  Clin Immunol       Date:  2009-06-25       Impact factor: 3.969

9.  Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype.

Authors:  George P Christophi; Michael Panos; Chad A Hudson; Rebecca L Christophi; Ross C Gruber; Akos T Mersich; Scott D Blystone; Burk Jubelt; Paul T Massa
Journal:  Lab Invest       Date:  2009-04-27       Impact factor: 5.662

Review 10.  The Effect of COVID-19 on NF-κB and Neurological Manifestations of Disease.

Authors:  Don A Davies; Aida Adlimoghaddam; Benedict C Albensi
Journal:  Mol Neurobiol       Date:  2021-06-01       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.